Natural History of Treated Neurocysticercosis and Long-Term Outcomes

A vizsgálat adatai

Ki végzi

National Institute of Allergy and Infectious Diseases (NIAID)

Azonosító

NCT00001205

A regiszteradat frissítve

2026. október 29.

Eredeti leírás

Neurocysticercosis is a brain disease due to the larval stage of the pork tapeworm (Taenia solium). The most common symptoms patient experience from infection inside the substance of the brain (parenchymal disease) are seizures and headaches. When the infection is either inside the fluid pockets inside the brain (ventricular disease) or in the space around the brain (subarachnoid disease) patients can have chronic headaches, relapsing aseptic meningitis, hydrocephalus, stroke, and may require neurosurgical intervention. The purpose of this study is to treat patients with anthelmintic therapy (praziquantel and/or albendazole) and anti-inflammatories in alignment with currently accepted best practices and guidelines, depending on the neurocysticercosis subtype. The purpose of the study is to better understand and characterize clinical, biologic, and management factors during treatment that influence long term outcomes. In order to understand this further we collect patient clinical information, patient survey responses, blood, urine samples, and additional cerebral spinal fluid if already being collected for clinical care.A teljes eredeti leírásKevesebb

Neurocysticercosis is a brain disease due to the larval stage of the pork tapeworm (Taenia solium). The most common symptoms patient experience from infection inside the substance of the brain (parenchymal disease) are seizures and headaches. When the infection is either inside the fluid pockets inside the brain (ventricular disease) or in the space around the brain (subarachnoid disease) patients can have chronic headaches, relapsing aseptic meningitis, hydrocephalus, stroke, and may require neurosurgical intervention. The purpose of this study is to treat patients with anthelmintic therapy (praziquantel and/or albendazole) and anti-inflammatories in alignment with currently accepted best practices and guidelines, depending on the neurocysticercosis subtype. The purpose of the study is to better understand and characterize clinical, biologic, and management factors during treatment that influence long term outcomes. In order to understand this further we collect patient clinical information, patient survey responses, blood, urine samples, and additional cerebral spinal fluid if already being collected for clinical care.

Kizáró feltételek: Not applicable.

INCLUSION CRITERIA:; Arms 1-5 (NCC):; Aged 3 years and older; Ability of participant (or legally authorized representative, LAR) to understand and the willingness to sign a written informed consent document; Patients with proven or likely NCC; Arm 6 (Endemic Exposures):; Patient with epidemiologic history compatible with possible exposure to NCC; Aged 18 years and older.

ClinicalTrials.gov NCT00001205